Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 116.87B +49.9% |
| Revenue (ttm) | 43.05B +3.1% |
| Net Income | 8.12B +83.8% |
| EPS | 3.98 +82.7% |
| Shares Out | n/a |
| PE Ratio | 14.38 |
| Forward PE | 10.15 |
| Dividend | 2.16 (3.94%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 3,599 |
| Open | 56.53 |
| Previous Close | 56.40 |
| Day's Range | 54.85 - 57.33 |
| 52-Week Range | 36.65 - 60.64 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
News
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol-Myers Squibb ($BMY) fell by more than 3%. This came…
Bristol Myers upgraded to Buy from Hold at Argus
Argus analyst Jasper Hellweg upgraded Bristol Myers (BMY) to Buy from Hold with a $75 price target Bristol Myers is showing signs of a turnaround as growth products and new…
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
AstraZeneca (AZN) and Bristol Myers (BMY) are not engaged in merger discussions, ending speculation around a potential $400B pharmaceutical combination, Reuters’ Maggie Fick and Sabrina Valle report. ...
Schrodinger announces collaboration, software agreement with Bristol Myers
Schrodinger (SDGR) announced a strategic agreement with Bristol Myers Squibb (BMY) to deploy Bunsen, Schrodinger’s agentic AI co-scientist, within its research organization. The new agreement signific...
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a moot...
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
AstraZeneca’s (AZN) merger talks with Bristol Myers (BMY) remain active, Liz Hoffman of Semafor reports. A potential deal would move AstraZeneca’s revenues further away from the UK and Europe and…
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
TD Cowen analyst Steve Scala doesn’t see logic in combination of AstraZeneca (AZN) and Bristol Myers (BMY). If combined, AstraZeneca’s 2027-2032 sales growth would be diluted by two percentage points,...
Astra Buying Bristol Makes No Sense, Fazeli Says
AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers.
Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According...
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
5 Things to Know Before the Stock Market Opens on Monday
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...
Citi views report of AstraZeneca, Bristol Myers talks as surprising
Citi analyst Graham Parry is surprised by the Financial Times report of a potential merger between AstraZeneca (AZN) and Bristol Myers (BMY). The firm believes Astra’s pipeline is “best-in-sector” and...
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the...
Bristol Myers price target raised to $70 from $66 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Bristol Myers (BMY) to $70 from $66 and keeps a Neutral rating on the shares. The firm updated models in…
AstraZeneca holds talks with US cancer drug developer in $400bn merger
Bristol Myers Squibb tie-up would be one of biggest-ever pharma deals and create world's fourth-largest drugmaker
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb had a total valuation of $133 billi...
AstraZeneca drops 6% to $159.98 after report of Bristol Myers merger talks
05:01 EDT AstraZeneca (AZN) drops 6% to $159.98 after report of Bristol Myers (BMY) merger talks
Bristol Myers jumps 8% to $70.47 after report of AstraZeneca merger talks
05:02 EDT Bristol Myers (BMY) jumps 8% to $70.47 after report of AstraZeneca (AZN) merger talks
Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?
AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a p...
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks
If maintained until close, the decline would be the stock's biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal. If completed, a combined company could be valued at roughly roughly $400 billion.
AstraZeneca shares tumble 7% after reported Bristol Myers talks
AstraZeneca shares tumbled 7% in early trading on Monday following reports of talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.
AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal
British drugmaker AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) are in early talks about a potential merger that could create a $400 billion pharmaceutical giant, according to the Fina...